drugset / Trial / NCT02225704
Radium-223 in Combination With Enzalutamide
NaSingle-groupOpen-labelTreatment
Summary
This study aims to determine the safety and tolerability of Radium-223 when administered in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
Timeline
- Start
- 2015-06-03
- Primary completion
- 2017-07
- Completion
- 2021-11-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Radium-223 dichloride | Other / unclassified | 0.05 mbq/kg | Intravenous |
| Background | Enzalutamide | Other / unclassified | 160 mg | Oral |